Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Bristol Myers Squibb (BMYMP) Change in Receivables (2016 - 2025)

Historic Change in Receivables for Bristol Myers Squibb (BMYMP) over the last 17 years, with Q4 2025 value amounting to -$19.0 million.

  • Bristol Myers Squibb's Change in Receivables rose 8671.33% to -$19.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $295.0 million, marking a year-over-year increase of 21174.24%. This contributed to the annual value of $295.0 million for FY2025, which is 21174.24% up from last year.
  • Bristol Myers Squibb's Change in Receivables amounted to -$19.0 million in Q4 2025, which was up 8671.33% from -$155.0 million recorded in Q3 2025.
  • In the past 5 years, Bristol Myers Squibb's Change in Receivables ranged from a high of $1.0 billion in Q2 2024 and a low of -$786.0 million during Q1 2022
  • Its 5-year average for Change in Receivables is $137.2 million, with a median of $137.0 million in 2021.
  • In the last 5 years, Bristol Myers Squibb's Change in Receivables tumbled by 107313.43% in 2022 and then soared by 146769.23% in 2024.
  • Over the past 5 years, Bristol Myers Squibb's Change in Receivables (Quarter) stood at $168.0 million in 2021, then crashed by 36.9% to $106.0 million in 2022, then soared by 379.25% to $508.0 million in 2023, then tumbled by 128.15% to -$143.0 million in 2024, then skyrocketed by 86.71% to -$19.0 million in 2025.
  • Its Change in Receivables stands at -$19.0 million for Q4 2025, versus -$155.0 million for Q3 2025 and $484.0 million for Q2 2025.